<DOC>
	<DOCNO>NCT02207413</DOCNO>
	<brief_summary>The purpose trial demonstrate acceptable safety profile immunological non-inferiority FLU D-QIV vaccine manufacture investigational process ( FLU D-QIV Investigational Process [ IP ] ) compare FLU D-QIV manufacture current licensed process ( FLU D-QIV Licensed Process [ LP ] ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity GlaxoSmithKline ( GSK ) Biologicals ' Quadrivalent Influenza Candidate Vaccine ( GSK2321138A ) Manufactured Using New Process Adults Children</brief_title>
	<detailed_description>This study enroll 3 age cohort : Adults : 18-49 year , Children : 3-17 year 6-35 month age .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<criteria>Adults 1849 year cohort : A male female , include , 18 49 year age time vaccination . Subjects investigator believe they/their parent ( ) /Legally Acceptable Representatives ( LAR ( ) ) comply requirement protocol . Written inform consent obtain subject/parent ( ) /LAR ( ) subject . Written inform assent obtain subject if/as require local regulation . Healthy subject chronic wellcontrolled disease establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception 2 month vaccination . Pediatric cohort : United States : • A male female subject , include , age 3 17 year United States . Rest World : • A male female subject , include , age 6 month 17 year country exception United States . All participate country : Subjects investigator believe they/their parent ( ) /Legally Acceptable Representatives ( LAR ( ) ) comply requirement protocol . Written inform consent obtain subject/parent ( ) /LAR ( ) subject . Written inform assent obtain subject if/as require local regulation . Healthy subject chronic wellcontrolled disease establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Adults age 1849 year cohort : Child care . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical device ) . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within 6 month prior first vaccine dose . Inhaled topical steroid allow . Any confirmed suspected immunosuppressive immunodeficient condition base medical history physical examination . Any administration longacting immunemodifying drug within 6 month study start , plan administration study period . Administration influenza vaccine 6 month precede entry study . Administration vaccine foreseen study protocol within 30 day vaccination plan administration study period . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Any known suspected allergy constituent influenza vaccine ( include egg protein ) ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Acute uncontrolled , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory test . Any history GuillainBarré Syndrome . Acute disease and/or fever time enrolment . Fever define temperature ≥ 38.0ºC/100.4ºF . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . History chronic alcohol consumption and/or drug abuse . Any contraindication intramuscular administration influenza vaccine . Any condition , opinion investigator , prevents subject participate study . Pediatric cohort Child care . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical device ) . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within 6 month prior first vaccination dose . Inhaled topical steroid allow . Any confirmed suspected immunosuppressive immunodeficient condition base medical history physical examination . Any administration longacting immunemodifying drug within 6 month study start , plan administration study period . Administration influenza vaccine 6 month precede entry study . Administration vaccine foreseen study protocol within 30 day vaccination plan administration study period . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Any known suspected allergy constituent influenza vaccine ( include egg protein ) ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Acute uncontrolled , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory test . Any history GuillainBarré Syndrome . Acute disease and/or fever time enrolment . Fever define temperature ≥ 38.0ºC/100.4ºF . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . History chronic alcohol consumption and/or drug abuse . Any contraindication intramuscular administration influenza vaccine . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Quadrivalent influenza vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Children</keyword>
	<keyword>Adults</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>